Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 5/20 | 0.75 |
| ▸ | MAP3K11 | Q16584 | 11/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30521879 | 1.00 | FYN (1.00) | FYNMTORMAP3K11GRIN1GRIN2B | |
| SCHEMBL4266971 | 0.90 | FYN (0.82) | FYNMTORMAP3K11LRRK2 | |
| SCHEMBL4270835 | 0.90 | FYN (0.82) | FYNMTORMAP3K11LRRK2 | |
| SCHEMBL4272310 | 0.90 | FYN (0.81) | FYNMTORMAP3K11GRIN1GRIN2B | |
| SCHEMBL4268299 | 0.90 | FYN (0.81) | FYNMTORMAP3K11GRIN1GRIN2B | |
| SCHEMBL4269001 | 0.90 | FYN (0.81) | FYNMTORMAP3K11LRRK2 | |
| SCHEMBL4268264 | 0.87 | FYN (0.77) | FYNMTORMAP3K11LRRK2 | |
| SCHEMBL4275364 | 0.86 | FYN (0.76) | FYNMTORMAP3K11LRRK2 | |
| SCHEMBL4269013 | 0.86 | FYN (0.76) | FYNMTORMAP3K11GRIN1GRIN2B | |
| SCHEMBL4271613 | 0.85 | FYN (0.75) | FYNMTORMAP3K11GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | claimed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | claimed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | claimed |
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2024-02-08 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | Pathways Neuro Pharma, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2021-02-04 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | Pathways Neuro Pharma, Inc. | 2020-06-23 | — | — | US | disclosed |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | Pathways Neuro Pharma, Inc. | 2018-09-06 | — | — | US | disclosed |
| EP-3347462-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | Lau, Warren C. (US) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017044623-A1 | METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS | LAU WARREN C (US) | 2017-03-16 | — | — | WO | disclosed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-7608622-B2 | 1 -Phenylerhyl)-6-(3,4,5-trimethoxyphenyl)- 1 ,3-dihydroimidazo[4,5-b]pyrazin-2-one; | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-27 | — | — | US | disclosed |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041868-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885MTOR 671/4885MAP3K11 56/4885 |
| US-20060106022-A1 | Imidazo[4,5-b]pyrazinone inhibitors of protein kinases | AURKA, AURKC, AURKB | FYN 645/4885MTOR 414/4885MAP3K11 116/4885 |
| US-20180250297-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885MTOR 671/4885MAP3K11 56/4885 |
| US-11701353-B2 | Methods, compositions, and uses of novel FYN kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885MTOR 671/4885MAP3K11 56/4885 |
| US-10688093-B2 | Methods, compositions, and uses of novel Fyn kinase inhibitors | FYN, LCK, PTK2B | FYN 1/4885MTOR 671/4885MAP3K11 56/4885 |
| US-20210030753-A1 | Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors | FYN, LCK, PTK2B | FYN 1/4885MTOR 671/4885MAP3K11 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.